Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ZIAGEN 20 MG/ML SOLUTION

abacavir sulfate
$0.5865per ML

Strength

20 mg/mL

Manufacturer

ViiV Healthcare Company

NDC

49702022248

Classification

Brand

Dosage Form

SOLUTION

Route

ORAL

Last Updated

12/17/2014

Active Ingredients

ABACAVIR SULFATE

Approval Type

New Drug (NDA)

FDA Application

NDA020978

On Market Since

1/28/1999

Pharmacological Classes

Cytochrome P450 1A1 Inhibitors
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

N/A

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

EPIVIR 10 MG/ML ORAL SOLN
Brand
49702020548•ViiV Healthcare Company
$0.4452
per ML
EPIVIR 150 MG TABLET
Brand
49702020318•ViiV Healthcare Company
$6.6144
per EA
INTELENCE 100 MG TABLET
Brand
59676057001•Janssen Products LP
$10.9213
per EA
EPIVIR 300 MG TABLET
Brand
49702020413•ViiV Healthcare Company
$13.2940
per EA
COMBIVIR TABLET
Brand
49702020218•ViiV Healthcare Company
$14.3948
per EA
EMTRIVA 200 MG CAPSULE
Brand
61958060101•Gilead Sciences, Inc.
$17.4370
per EA
INTELENCE 200 MG TABLET
Brand
59676057101•Janssen Products LP
$24.2861
per EA
VIREAD 300 MG TABLET
Brand
61958040101•Gilead Sciences, Inc.
$40.7318
per EA
BARACLUDE 1 MG TABLET
Brand
00003161212•E.R. Squibb & Sons, L.L.C.
$43.9221
per EA
BARACLUDE 0.5 MG TABLET
Brand
00003161112•E.R. Squibb & Sons, L.L.C.
$44.1865
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy